153 related articles for article (PubMed ID: 35565207)
1. Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P).
Hölscher T; Baumann M; Kotzerke J; Zöphel K; Paulsen F; Müller AC; Zips D; Thomas C; Wirth M; Troost EGC; Krause M; Löck S; Lohaus F
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565207
[TBL] [Abstract][Full Text] [Related]
2. Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial.
Hölscher T; Baumann M; Kotzerke J; Zöphel K; Paulsen F; Müller AC; Zips D; Koi L; Thomas C; Löck S; Krause M; Wirth M; Lohaus F
Eur Urol Oncol; 2022 Feb; 5(1):44-51. PubMed ID: 34785189
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
4. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
5. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
Lohaus F; Zöphel K; Löck S; Wirth M; Kotzerke J; Krause M; Baumann M; Troost EGC; Hölscher T
Eur Urol; 2019 Apr; 75(4):548-551. PubMed ID: 30578119
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
7. Metastasis-directed Therapy (SBRT) Guided by PET-CT
Mazzola R; Francolini G; Triggiani L; Napoli G; Cuccia F; Nicosia L; Livi L; Magrini SM; Salgarello M; Alongi F
Clin Genitourin Cancer; 2021 Jun; 19(3):230-236. PubMed ID: 32863189
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ
Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639
[TBL] [Abstract][Full Text] [Related]
9.
Marzec J; Becker J; Paulsen F; Wegener D; Olthof SC; Pfannenberg C; Schwenck J; Bedke J; Stenzl A; Nikolaou K; la Fougère C; Zips D; Müller AC
Acta Oncol; 2020 Feb; 59(2):149-156. PubMed ID: 31559880
[No Abstract] [Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. Patterns of Progression After
Soldatov A; von Klot CAJ; Walacides D; Derlin T; Bengel FM; Ross TL; Wester HJ; Derlin K; Kuczyk MA; Christiansen H; Henkenberens C
Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):95-104. PubMed ID: 30201438
[TBL] [Abstract][Full Text] [Related]
12. The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients.
Guler OC; Engels B; Onal C; Everaert H; Van den Begin R; Gevaert T; de Ridder M
Clin Transl Oncol; 2018 Apr; 20(4):484-490. PubMed ID: 28795303
[TBL] [Abstract][Full Text] [Related]
13. Comparison of
Walacides D; Meier A; Knöchelmann AC; Meinecke D; Derlin T; Bengel FM; Ross TL; Wester HJ; Derlin K; Kuczyk MA; von Klot CAJ; Christiansen H; Henkenberens C
Strahlenther Onkol; 2019 May; 195(5):420-429. PubMed ID: 30610354
[TBL] [Abstract][Full Text] [Related]
14. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
[TBL] [Abstract][Full Text] [Related]
15. Progression-free survival in patients with
Werensteijn-Honingh AM; Wevers AFJ; Peters M; Kroon PS; Intven M; Eppinga WSC; Jürgenliemk-Schulz IM
Acta Oncol; 2021 Oct; 60(10):1342-1351. PubMed ID: 34323648
[TBL] [Abstract][Full Text] [Related]
16.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
17. Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [
Vogel MME; Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Mix M; la Fougère C; Eiber M; Christiansen H; Belka C; Grosu AL; Müller AC; Guckenberger M; Combs SE
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2328-2338. PubMed ID: 32179961
[TBL] [Abstract][Full Text] [Related]
18. PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study.
Mazzola R; Cuccia F; Pastorello E; Salgarello M; Francolini G; Livi L; Triggiani L; Magrini SM; Ingrosso G; Aristei C; Franzese C; Scorsetti M; Alongi F
Clin Exp Metastasis; 2022 Jun; 39(3):443-448. PubMed ID: 35266063
[TBL] [Abstract][Full Text] [Related]
19. PSMA-PET guided dose-escalated volumetric arc therapy (VMAT) for newly diagnosed lymph node positive prostate cancer: Efficacy and toxicity outcomes at two years.
Shakespeare TP; Eggert E; Wood M; Westhuyzen J; Turnbull K; Rutherford N; Aherne N
Radiother Oncol; 2019 Dec; 141():188-191. PubMed ID: 31668514
[TBL] [Abstract][Full Text] [Related]
20. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer.
Jereczek-Fossa BA; Beltramo G; Fariselli L; Fodor C; Santoro L; Vavassori A; Zerini D; Gherardi F; Ascione C; Bossi-Zanetti I; Mauro R; Bregantin A; Bianchi LC; De Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):889-97. PubMed ID: 21277113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
